Trial Profile
Clinical Study of the Efficacy of the Ophthalmic Solution of Pazufloxacin 0.6% (PRO-157) for the Treatment of Acute Bacterial Conjunctivitis, Compared to the Ophthalmic Solution of Gatifloxacin 0.3%
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 25 Aug 2021
Price :
$35
*
At a glance
- Drugs Pazufloxacin (Primary) ; Gatifloxacin
- Indications Bacterial infections; Infectious conjunctivitis
- Focus Registrational; Therapeutic Use
- Sponsors Laboratorios Sophia
- 02 Aug 2021 Status changed from recruiting to discontinued.
- 08 May 2019 Status changed from active, no longer recruiting to recruiting.
- 11 Oct 2018 New trial record